Rare Genetic Variations Linked to Schizophrenia
|
By LabMedica International staff writers Posted on 09 Dec 2016 |

Image: Chromosome ideograms showing some locations of genome-wide significant linkages in schizophrenia and bipolar disorder. Asterisks mark the locations of chromosomal abnormalities associated with schizophrenia (Photo courtesy of SPL).
Genetic variations that increase schizophrenia risk are rare, making it difficult to study their role and to overcome this. Recently, the genomes of more than 41,000 people have been analyzed in the largest study of its kind to date.
The mutations, known as copy number variants, are deletions or duplications of the DNA sequence. A copy number variant (CNC) may affect dozens of genes, or it can disrupt or duplicate a single gene. This type of variation can cause significant alterations to the genome and lead to psychiatric disorders.
A large team of international scientists led by those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed the genomes of 21,094 people with schizophrenia and 20,227 people without schizophrenia. They found eight locations in the genome with copy number variants associated with schizophrenia risk. Only a small fraction of cases (1.4%) carried these variants. The team also found that these copy number variants occurred more frequently in genes involved in the function of synapses, the connections between brain cells that transmit chemical messages.
Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by non-allelic homologous recombination. With its large sample size, this study had the power to find copy number variants with large effects that occur in more than 0.1%of schizophrenia cases. However, the team said they are still missing many variants. More analyses will be needed to detect risk variants with smaller effects, or ultra-rare variants.
Jonathan Sebat, PhD, a Professor of Psychiatry and Cellular and Molecular Medicine and the lead investigator of the study said, “This study represents a milestone that demonstrates what large collaborations in psychiatric genetics can accomplish. We are confident that applying this same approach to a lot of new data will help us discover additional genomic variations and identify specific genes that play a role in schizophrenia and other psychiatric conditions.” The study was published on November 21, 2016, in the journal Nature Genetics.
Related Links:
University of California, San Diego School of Medicine
The mutations, known as copy number variants, are deletions or duplications of the DNA sequence. A copy number variant (CNC) may affect dozens of genes, or it can disrupt or duplicate a single gene. This type of variation can cause significant alterations to the genome and lead to psychiatric disorders.
A large team of international scientists led by those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed the genomes of 21,094 people with schizophrenia and 20,227 people without schizophrenia. They found eight locations in the genome with copy number variants associated with schizophrenia risk. Only a small fraction of cases (1.4%) carried these variants. The team also found that these copy number variants occurred more frequently in genes involved in the function of synapses, the connections between brain cells that transmit chemical messages.
Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by non-allelic homologous recombination. With its large sample size, this study had the power to find copy number variants with large effects that occur in more than 0.1%of schizophrenia cases. However, the team said they are still missing many variants. More analyses will be needed to detect risk variants with smaller effects, or ultra-rare variants.
Jonathan Sebat, PhD, a Professor of Psychiatry and Cellular and Molecular Medicine and the lead investigator of the study said, “This study represents a milestone that demonstrates what large collaborations in psychiatric genetics can accomplish. We are confident that applying this same approach to a lot of new data will help us discover additional genomic variations and identify specific genes that play a role in schizophrenia and other psychiatric conditions.” The study was published on November 21, 2016, in the journal Nature Genetics.
Related Links:
University of California, San Diego School of Medicine
Latest Molecular Diagnostics News
- Targeted RNA Test Enhances Genetic Diagnosis in Exome Sequencing
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








